Characteristics Of Physical Condition Of Futsal Athletes In Cianjur District

The purpose of this study was to determine the physical condition of futsal athletes in the Provincial Sports Week Qualification Round. The method used is descriptive quantitative with test and measurement techniques. The population consists of 16 Futsal Futsal Athletes in the Qualification Round of the Provincial Sports Week, and will then be used as research samples. The instrument used is a test and measurement of physical condition of Endurance, Power, Agility, Speed ​​and Flexibility. Data analysis using T score. Based on the results of the analysis showed that the profile of physical condition in physical condition was in the good category with a percentage of 94% (15 people), in physical condition in the moderate category with a percentage of 6% (1 person). With an average of 17, the analysis of the physical condition of the BK Cianjur BK futsal athletes in 2021 is in the good category. That the results of the analysis show that the profile of the physical condition of the futsal athlete BK Porda Cianjur Regency in 2021 is in a good category, so the coach advises the player to better maintain physical condition towards preparation for the Qualification Round of the Provincial Sports Week, so that the training program can be adapted to the athlete's physical condition. This requires a lot of programmed training to increase the physical condition of the players

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk